Advertisement

Topics

Nordic updates on CTA for Archer─1 and PARADIGME trials in Norway

14:08 EDT 29 May 2018 | PharmaBiz

Nordic Nanovector ASA has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer─1 phase 1b trial with Betalutin

Original Article: Nordic updates on CTA for Archer─1 and PARADIGME trials in Norway

NEXT ARTICLE

More From BioPortfolio on "Nordic updates on CTA for Archer─1 and PARADIGME trials in Norway"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioethics
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...